Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Dec 05 | 2023Zealand 2023 Investor Day Obesity Pipeline Updates; Zepbound Now Available; Inventiva Receives DMC Approval to Continue Ph3 MASH Trial; Ascensia Participates in Film Series for Eversense CGMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Dec 04 | 2023Roche to Acquire Carmot; 89bio Ph3 MASH ProgramPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Dec 01 | 2023Pfizer Loses and Altimmune Wins with New Ph2 Obesity DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Nov 30 | 2023Arrowhead CY Q3 ’23 (FY Q4 ’23) Earnings; Zealand Appoints Enrique Conterno and Elaine Sullivan as Board ObserversPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery Nov 29 | 2023SAB Initiates Ph1 T1DM study; Lilly Continues Verve Investment; Arecor Expands Collaboration with Lilly; Avidity Expands CV Partnership with BMSPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Nov 28 | 2023Novartis 2023 Investor Day Pipeline Updates; New Lilly Obesity AssetPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 28 | 2023Novo Expands Production Facilities in France; Novo to Reduce Production of Victoza for Ozempic Supply; Mounjaro vs. Ozempic in Real-World Study; Kaleido Launches AID System; Biodexa Acquires T1DM Asset; 89bio Long-term MASH Data; Dario Contracts for Cardiometabolic SolutionPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other Nov 21 | 2023Medtronic CY Q3 ’23 (FY Q2 ’24) Earnings; Lilly to Build Production Plant in Germany; Lilly Initiates Ph1 T2DM Study; Carmot Files for IPOPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Nov 21 | 2023Zepbound (tirzepatide) Label and Website AnalysisPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Nov 15 | 2023Novo Initiates Ph2 Cagrisema Trial in CKD and T2DM; Carmot Initiates Ph2 GLP-1/GIP RA Study in Obesity and T1DM; OptumRx Lowers Insulin Costs; Beta Bionics Gains Coverage for iLet Bionic Pancreas; Mark Estes Joins Biolinq; Belgium and Britain Ban Ozempic for Weight LossPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Nov 14 | 2023Novo H2H Cagrisema vs. Tirzepatide Trial; Terns and Nemaura Q3 ’23 Earnings; Viking Ph2b MASH Data at AASLD; SAB Therapeutics Raises $67.1M for T1DM Treatment; Dexcom Launches #SeeDiabetes CampaignPurchase Blast
$599
Posted in: Other, SGLT2i Nov 13 | 2023AHA 2023: Roche/Alnylam, Amgen, Amarin, Esperion, and Lexicon Present New Data; Cleerly Partner Participation in TRANSFORM HF TrialPurchase Blast
$599
Nov 13 | 2023Galectin and Akero Q3 ’23 Earnings; 89bio Presents Additional MASH Data at AASLD 2023; Dario Announces New Integrated Cardiometabolic Solution ResearchPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Nov 11 | 2023SELECT Lives Up to the Hype; Full SELECT Results at AHA 2023Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Nov 10 | 2023Lilly’s Mounjaro Receives Positive CHMP Opinion for Obesity; Lilly at UBS 2023; Novo Expands Existing Manufacturing Facilities; Madrigal Appoints Carole Huntsman as CCO; Madrigal, Akero, and Boston Present MASH Data at AASLD 2023; Diabetes Care Survey ResultsPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 10 | 2023Novo to Discontinue Levemir; Lilly Initiates Ph2 GLP-1/GCG RA Trial; Zealand, Lexicon, Senseonics, Xeris, and Bayer Q3 ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Nov 09 | 2023AZ Buys Oral GLP-1RA; Q3 ’23 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, Insulin Delivery, Other Nov 08 | 2023OrsoBio Secures $60M in Series A Funding with Lilly as a New Investor; Diamyd Collaborates with DiaUnion for Ph2 T1DM Trial Recruitment; Esperion, Altimmune, MannKind, and Viatris Q3 ’23 EarningsPurchase Blast
$599
Posted in: GLP-1RA Nov 08 | 2023Tirzepatide Obesity Indication Approved as “Zepbound” Purchase Blast